NO20012106L - Middel for behandling av forstyrrelser i benmetabolismen - Google Patents

Middel for behandling av forstyrrelser i benmetabolismen

Info

Publication number
NO20012106L
NO20012106L NO20012106A NO20012106A NO20012106L NO 20012106 L NO20012106 L NO 20012106L NO 20012106 A NO20012106 A NO 20012106A NO 20012106 A NO20012106 A NO 20012106A NO 20012106 L NO20012106 L NO 20012106L
Authority
NO
Norway
Prior art keywords
disorders
treatment
bone metabolism
metabolism
bone
Prior art date
Application number
NO20012106A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012106D0 (no
Inventor
Shinichi Mochizuki
Nobuaki Fujise
Chiharu Masuyama
Eisuke Tsuda
Kanji Higashio
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20012106D0 publication Critical patent/NO20012106D0/no
Publication of NO20012106L publication Critical patent/NO20012106L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
NO20012106A 1998-10-28 2001-04-27 Middel for behandling av forstyrrelser i benmetabolismen NO20012106L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32287498 1998-10-28
PCT/JP1999/005963 WO2000024416A1 (fr) 1998-10-28 1999-10-28 Agents therapeutiques pour deformations osseuses

Publications (2)

Publication Number Publication Date
NO20012106D0 NO20012106D0 (no) 2001-04-27
NO20012106L true NO20012106L (no) 2001-06-21

Family

ID=18148585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012106A NO20012106L (no) 1998-10-28 2001-04-27 Middel for behandling av forstyrrelser i benmetabolismen

Country Status (21)

Country Link
US (1) US6919312B2 (zh)
EP (1) EP1127578A4 (zh)
JP (1) JP3860415B2 (zh)
KR (1) KR20010082272A (zh)
CN (1) CN1183961C (zh)
AU (1) AU755422B2 (zh)
BR (1) BR9914834A (zh)
CA (1) CA2347107A1 (zh)
CZ (1) CZ20011378A3 (zh)
HK (1) HK1042847A1 (zh)
HU (1) HUP0104126A3 (zh)
IL (1) IL142557A0 (zh)
MX (1) MXPA01004225A (zh)
NO (1) NO20012106L (zh)
NZ (1) NZ511506A (zh)
PL (1) PL347559A1 (zh)
RU (1) RU2223782C2 (zh)
TR (1) TR200101146T2 (zh)
TW (1) TW529954B (zh)
WO (1) WO2000024416A1 (zh)
ZA (1) ZA200103296B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
BR9914834A (pt) 1998-10-28 2001-08-14 Snow Brand Milk Products Co Ltd Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
EP1377610A2 (en) 2001-04-03 2004-01-07 Société des Produits Nestlé S.A. Osteoprotegerin in milk
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
TW200820980A (en) * 2006-10-02 2008-05-16 Nat Inst For Materials Science A sustained-release preparation having osteoconductive activity
US20090028954A1 (en) * 2006-12-22 2009-01-29 Mathys Ag Bettlach Precursor for the preparation of a pasty bone replacement material by admixture of a liquid
SG181615A1 (en) * 2009-12-09 2012-07-30 Agency Science Tech & Res Glycosaminoglycan mixtures
CN111454899B (zh) * 2020-04-30 2021-04-20 青岛思拓新源细胞医学有限公司 角叉菜多糖在抑制间充质干细胞成脂转化中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
IL91438A (en) * 1989-08-25 1995-03-30 Bukh Meditec Preparation for treating dental disease
TW318142B (zh) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
CN1138786C (zh) 1997-04-15 2004-02-18 三共株式会社 识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
RU2203497C2 (ru) 1997-09-24 2003-04-27 Санкио Компани Лимитед Способ диагностики метаболических костных заболеваний
WO1999065916A1 (en) 1998-06-15 1999-12-23 Takeda Chemical Industries, Ltd. Thienodipyridine derivatives, production and use thereof
BR9914834A (pt) 1998-10-28 2001-08-14 Snow Brand Milk Products Co Ltd Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
AR026946A1 (es) 1999-12-16 2003-03-05 Amgen Inc Osteoprotegerina/receptores de factores de necrosis de tumores
EP1270015A3 (en) 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor

Also Published As

Publication number Publication date
AU6487799A (en) 2000-05-15
CN1183961C (zh) 2005-01-12
MXPA01004225A (es) 2002-06-04
US20010031725A1 (en) 2001-10-18
TR200101146T2 (tr) 2001-09-21
NO20012106D0 (no) 2001-04-27
US6919312B2 (en) 2005-07-19
HUP0104126A2 (hu) 2002-03-28
HUP0104126A3 (en) 2004-07-28
IL142557A0 (en) 2002-03-10
NZ511506A (en) 2004-02-27
PL347559A1 (en) 2002-04-08
CZ20011378A3 (cs) 2001-10-17
RU2223782C2 (ru) 2004-02-20
AU755422B2 (en) 2002-12-12
JP3860415B2 (ja) 2006-12-20
TW529954B (en) 2003-05-01
WO2000024416A1 (fr) 2000-05-04
EP1127578A4 (en) 2004-12-15
HK1042847A1 (zh) 2002-08-30
CN1325310A (zh) 2001-12-05
BR9914834A (pt) 2001-08-14
ZA200103296B (en) 2001-10-25
KR20010082272A (ko) 2001-08-29
CA2347107A1 (en) 2000-05-04
EP1127578A1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
NO993051L (no) Intranasale formuleringer for behandling av seksuelle forstyrrelser
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
NO20004688D0 (no) Terapi ved østrogenassosierte lidelser
AU6910600A (en) Methods for the treatment of mental disorders
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
HUP0201791A2 (en) The use of escitalopram for treatment of neurotic disorders
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
AU6330999A (en) Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
NO20013146L (no) Middel for behandling av synscellefunksjonsforstyrrelse
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
PT1051172E (pt) Metodo para tratamento da dpco
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
NO20012616D0 (no) Middel til behandling av erektil malfunksjon
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
DK82798A (da) Treatment of GABA-uptake related disorders
NO996166L (no) FremgangsmÕte for behandling av avluter